tradingkey.logo
tradingkey.logo
Suchen

ANI Pharmaceuticals Inc

ANIP
Zur Watchlist hinzufügen
78.010USD
-1.570-1.97%
Handelsschluss 05/15, 16:00ETKurse um 15 Minuten verzögert
1.77BMarktkapitalisierung
18.96KGV TTM

ANI Pharmaceuticals Inc

78.010
-1.570-1.97%

mehr Informationen über ANI Pharmaceuticals Inc Unternehmen

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.

ANI Pharmaceuticals Inc Informationen

BörsenkürzelANIP
Name des UnternehmensANI Pharmaceuticals Inc
IPO-datumMay 04, 2000
CEOLalwani (Nikhil Suresh)
Anzahl der mitarbeiter897
WertpapierartOrdinary Share
GeschäftsjahresendeMay 04
Addresse210 Main Street West
StadtBAUDETTE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl56623
Telefon12186343500
Websitehttps://www.anipharmaceuticals.com/
BörsenkürzelANIP
IPO-datumMay 04, 2000
CEOLalwani (Nikhil Suresh)

Führungskräfte von ANI Pharmaceuticals Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
311.43K
+0.42%
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
290.27K
-45.36%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
82.54K
-22.14%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
61.18K
-41.94%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
52.41K
-11.45%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
51.95K
-12.65%
Mr. Thomas Andrew (Thom) Rowland
Mr. Thomas Andrew (Thom) Rowland
Senior Vice President, Head of Established Brands
Senior Vice President, Head of Established Brands
37.85K
-12.61%
Mr. Thomas J. (Tom) Haughey, J.D.
Mr. Thomas J. (Tom) Haughey, J.D.
Independent Director
Independent Director
36.52K
--
Dr. Renee P. Tannenbaum, Pharm.D.
Dr. Renee P. Tannenbaum, Pharm.D.
Independent Director
Independent Director
25.16K
--
Mr. Matthew J. (Matt) Leonard
Mr. Matthew J. (Matt) Leonard
Independent Director
Independent Director
6.86K
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
311.43K
+0.42%
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
290.27K
-45.36%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
82.54K
-22.14%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
61.18K
-41.94%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
52.41K
-11.45%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
51.95K
-12.65%

Umsatzaufteilung

Währung: USDAktualisiert: Mon, Apr 6
Währung: USDAktualisiert: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Sales of generic pharmaceutical products
384.11M
43.48%
Sales of rare disease pharmaceutical products
347.78M
39.37%
Sales of Cortrophin Gel
347.78M
39.37%
Sales of branded pharmaceutical products
76.61M
8.67%
Nach RegionUSD
Name
Umsatz
Anteil
United States
852.44M
96.50%
International
30.92M
3.50%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Sales of generic pharmaceutical products
384.11M
43.48%
Sales of rare disease pharmaceutical products
347.78M
39.37%
Sales of Cortrophin Gel
347.78M
39.37%
Sales of branded pharmaceutical products
76.61M
8.67%

Aktionärsstatistik

Aktualisiert: Sun, May 10
Aktualisiert: Sun, May 10
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
10.76%
Meridian Venture Partners
4.46%
Vanguard Capital Management, LLC
3.62%
State Street Investment Management (US)
3.20%
Millennium Management LLC
2.37%
Andere
75.58%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
10.76%
Meridian Venture Partners
4.46%
Vanguard Capital Management, LLC
3.62%
State Street Investment Management (US)
3.20%
Millennium Management LLC
2.37%
Andere
75.58%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
42.89%
Investment Advisor/Hedge Fund
23.64%
Hedge Fund
20.43%
Research Firm
6.41%
Individual Investor
5.68%
Private Equity
4.46%
Pension Fund
2.51%
Corporation
1.92%
Bank and Trust
1.50%

Institutionelle Beteiligung

Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
555
23.15M
101.74%
+57.73K
2025Q4
507
21.97M
100.49%
+14.84K
2025Q3
525
21.96M
103.27%
+407.79K
2025Q2
506
21.46M
110.44%
-446.10K
2025Q1
489
21.61M
106.49%
-1.37M
2024Q4
469
21.12M
108.93%
+156.97K
2024Q3
453
20.75M
88.54%
+3.60M
2024Q2
425
17.36M
85.19%
+1.07M
2024Q1
403
16.22M
82.13%
-1.01M
2023Q4
390
16.10M
82.95%
+39.70K
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
2.45M
10.91%
+103.61K
+4.42%
Dec 31, 2025
Meridian Venture Partners
1.01M
4.53%
-150.00K
-12.88%
Aug 21, 2025
State Street Investment Management (US)
727.20K
3.24%
+15.50K
+2.18%
Dec 31, 2025
Millennium Management LLC
539.66K
2.41%
+474.42K
+727.14%
Dec 31, 2025
Dimensional Fund Advisors, L.P.
487.67K
2.18%
-17.76K
-3.51%
Dec 31, 2025
Soleus Capital Management, L.P.
486.24K
2.17%
+146.00K
+42.91%
Dec 31, 2025
Tang Capital Management, LLC
481.44K
2.15%
+163.94K
+51.63%
Dec 31, 2025
Deep Track Capital LP
477.68K
2.13%
+27.68K
+6.15%
Dec 31, 2025
Mehr Anzeigen

Verbundene ETFs

Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Invesco Pharmaceuticals ETF
2.63%
State Street SPDR S&P Pharmaceuticals ETF
2.42%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.95%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.63%
Innovator IBD Breakout Opportunities ETF
1.38%
Innovator IBD 50 Fund ETF
1.02%
Invesco Dorsey Wright Healthcare Momentum ETF
0.98%
Invesco S&P SmallCap Health Care ETF
0.96%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0.92%
First Trust Small Cap Growth AlphaDEX Fund
0.67%
Mehr Anzeigen
Invesco Pharmaceuticals ETF
Anteil2.63%
State Street SPDR S&P Pharmaceuticals ETF
Anteil2.42%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Anteil1.95%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Anteil1.63%
Innovator IBD Breakout Opportunities ETF
Anteil1.38%
Innovator IBD 50 Fund ETF
Anteil1.02%
Invesco Dorsey Wright Healthcare Momentum ETF
Anteil0.98%
Invesco S&P SmallCap Health Care ETF
Anteil0.96%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Anteil0.92%
First Trust Small Cap Growth AlphaDEX Fund
Anteil0.67%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
KeyAI